Skip to content
Home
Technology
Pipeline
Our Companies
Leadership
Leadership Voices
News & Events
Join Us
Contact
News & Events
Our latest news
[image placeholder – do not delete]
Select Company
All
Altavant
Enzyvant
Myovant
Spirovant
Sumitovant
Urovant
October 17, 2019
Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
October 10, 2019
Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
September 06, 2019
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
August 27, 2019
Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27, 2019
CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
August 20, 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
August 06, 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
July 23, 2019
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
July 22, 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
July 10, 2019
Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
« Previous
1
…
5
6
7
8
Next »